OptMed(OMED)

从VEGF/DLL4双抗“三兄弟”的前世今生，分析双抗研发策略

同写意2022-05-14 21:40

撰文丨顾津明，同润生物CSO
编辑丨于靖
近日，Compass Therapeutics公布了其VEGF/DLL4（CTX-009）双特异抗体联合紫杉醇在治疗胆道癌（BTC）的2期临床中期研究成果，结果表明该双抗药物安全性良好，在24名患者中有10位病人平均治疗6个月后得到了客观缓解，ORR为42%（10/24），算不上惊艳，...查看全文

Horned_Reaper2019-04-23 19:41

$Oncomed制药(OMED)$ 查看全文

Horned_Reaper2019-03-09 00:21

$Oncomed制药(OMED)$ 0.848加点仓，希望可以像SEEL一样起飞查看全文

Horned_Reaper2019-02-28 05:25

$Oncomed制药(OMED)$ 看来要再洗掉几层皮！航班开始无限期延误...[好困惑]查看全文

Horned_Reaper2019-02-21 05:51

$Oncomed制药(OMED)$ 看来飞机超载，要洗一洗才能起飞查看全文

Horned_Reaper2019-02-16 02:56

$Oncomed制药(OMED)$ 晚了一点起飞查看全文

Horned_Reaper2019-01-07 22:55

$Oncomed制药(OMED)$ 请收起小桌板，调直座椅靠背，系好安全带！查看全文

Horned_Reaper2019-01-04 23:35

$Oncomed制药(OMED)$ 随时要起飞的节奏…查看全文

有为的股价小宝石2018-12-27 00:15

$Oncomed制药(OMED)$ 要开涨了啊查看全文

usbiostock2018-08-03 09:49

$OncoMed Pharmaceuticals, Inc. (OMED)$ 1. Navicixizumab单药治疗实体瘤临床1a期试验一线数据预计：2018年第4季度；2. Etigilimab单药治疗进展性/转移性实体瘤临床1a期试验一线数据预计：2018年第4季度；3. 现金：$79.9M。查看全文

$OncoMed Pharmaceuticals, Inc.(OMED)$ 内部交易: 2018-04-24,See Remarks,Li Yvonne ,卖出,5062普通股, $2.68

$OncoMed Pharmaceuticals, Inc.(OMED)$ 8-K - Current report Filed: 2018-03-19 AccNo: 0001564590-18-006143 Size: 35 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers htt...

$OncoMed Pharmaceuticals, Inc.(OMED)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2018-03-09 AccNo: 0001564590-18-005014 Size: 10 MB 网页链接

$OncoMed Pharmaceuticals, Inc.(OMED)$ 8-K - Current report Filed: 2018-03-08 AccNo: 0001564590-18-004916 Size: 267 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接

$OncoMed Pharmaceuticals, Inc.(OMED)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2018-02-27 AccNo: 0001104659-18-012406 Size: 71 KB 网页链接

$OncoMed Pharmaceuticals, Inc.(OMED)$ 美东时间 2018-03-08 盘后 披露财报，预期EPS -0.31 网页链接

$OncoMed Pharmaceuticals, Inc.(OMED)$ 8-K/A [Amend] - Current report Filed: 2018-02-23 AccNo: 0001564590-18-003030 Size: 33 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Of...

$OncoMed Pharmaceuticals, Inc.(OMED)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2018-02-14 AccNo: 0001193125-18-045168 Size: 56 KB 网页链接

$OncoMed Pharmaceuticals, Inc.(OMED)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2018-02-14 AccNo: 0001144204-18-008710 Size: 119 KB 网页链接

$OncoMed Pharmaceuticals, Inc.(OMED)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2018-02-14 AccNo: 0001193125-18-045168 Size: 56 KB 网页链接